Gerresheimer's Interim Leadership Faces a Margin Test as €1.5bn Divestment Clock Ticks

The market's reaction on Wednesday told a quiet but revealing story. Gerresheimer shares climbed 3.7 percent to 27.78 euros after the Düsseldorf-based pharmaceutical packaging group published its first-quarter figures — a modest vote of confidence that investors were looking past the headline earnings decline and focusing instead on the company's shrinking footprint.

That narrowing is deliberate. The group has agreed to sell its Primary Packaging Plastics division and Centor US Holding to private equity firm Apax Partners in a deal valuing the combined businesses at 1.5 billion euros. Banks are reportedly arranging roughly one billion euros in debt financing, structured as leveraged loans alongside a revolving credit facility, with syndication to institutional investors slated for later this year. The Centor closing is expected before the end of the current fiscal year, while the Primary Packaging Plastics disposal should follow in the first half of 2027. Together, the divestments span 16 production sites across nine countries and approximately 2,400 employees.

The timing is awkward. Just over a week ago, interim CEO Uwe Röhrhoff announced his early departure despite a mandate that had been set to run until October. CFO Wolf Lehmann and board member Achim Schalk now share executive duties on an interim basis. Early this week, shareholders elected a new supervisory board — Rainer Beaujean, Markus Sieger and Eva van Pelt joined the panel, with Sieger assuming the chairmanship. Attendance at the vote reached 41.59 percent of share capital, and all resolutions passed.

A Margin Squeeze With a Counter-Narrative

The first-quarter numbers themselves present a split picture. Revenue edged up to 524 million euros from 519 million euros a year earlier, but adjusted EBITDA fell sharply to 66 million euros from 81 million euros, dragging the margin down from 15.7 percent to 12.6 percent. On the surface, that looks like deterioration. Yet free cash flow improved dramatically — a negative 32 million euros versus negative 141 million euros in the prior-year quarter, a swing of more than 100 million euros.

The division-level detail explains where the pressure is concentrated. Containment & Delivery Systems, the unit most aligned with the group's future direction, lifted revenue to 296 million euros with a healthy 20.6 percent margin. Moulded Glass tells a different story: sales slipped from 160 million euros to 144 million euros, while its margin collapsed from 20.1 percent to just 4.5 percent. That segment, not the businesses being sold, represents the real operational challenge.

The strategic logic behind the divestments is clear enough. Pharmaceutical manufacturers are demanding increasingly specialized supply chains for high-value delivery systems — injection solutions, syringes and containers for biologics. A presence in lower-margin commodity plastics packaging diluted that positioning. The Apax sale, agreed back in July, reads less as a fire sale and more as a calculated effort to concentrate on where the group actually creates value.

What Investors Are Watching Now

For shareholders, the central question is whether the interim leadership duo can stabilise the operating margin while simultaneously steering two complex corporate disposals to completion. The freed-up proceeds need to relieve the balance sheet before the GTO transformation programme delivers its planned EBITDA improvement of 50 to 70 million euros — a sequencing that will largely determine the share price trajectory in the months ahead.

JPMorgan, which reaffirmed its "Overweight" rating with a 46-euro price target in late August, acknowledged that quarterly revenue had beaten expectations but explicitly flagged the "significantly weaker operating result." That caveat underscores the margin vulnerability.

The shares currently trade at 27.98 euros, roughly 38 percent below the 52-week high of 44.88 euros reached last September, yet comfortably above the February trough of 14.90 euros. The stock sits about 13 percent above its 200-day moving average of 24.76 euros and just above the 50-day average of 27.50 euros — technical signs of a stabilisation that has been building for months. Annualised volatility of 51 percent, however, suggests investors remain deeply uncertain about the path ahead.

The Bull and Bear Cases

Optimists point to the sustained cash flow improvement and the prospect of a leaner, higher-margin business once the disposals complete. If Lehmann and Schalk can bridge the transition without further operational setbacks, the combination of debt reduction and sharper strategic focus could give the equity fresh momentum.

The bear case centres on the leadership vacuum coinciding with operational headwinds. An interim management team without a permanent CEO successor can hardly push through major strategic decisions, particularly while two complex divestments are being executed in parallel. Should either deal slip, or should EBITDA erosion persist for additional quarters, the supervisory board's refresh would likely be dismissed as a formality rather than embraced as a signal of confidence.

Management itself anticipates a stronger second half of fiscal 2026. Whether that materialises depends on how quickly Moulded Glass stabilises and how smoothly the Apax transactions close. The near-term test arrives with the Centor completion by fiscal year-end — a milestone that will reveal whether the group can slim down its portfolio on schedule while simultaneously searching for a permanent leadership structure. For now, Gerresheimer presents the unusual case of a balance sheet that looks uglier on paper than the underlying strategic narrative would suggest.